Showing results 8 to 25 of 25
< previous
Preview | Issue Date | Title | Author(s) |
| 2021 | Kidney age - chronological age difference (KCD) score provides an age-adapted measure of kidney function | Campbell, D.J.; Coller, J.M.; Gong, F.F.; McGrady, M.; Boffa, U.; Shiel, L.; Liew, D.; Stewart, S.; Owen, A.J.; Krum, H.; Reid, C.M.; Prior, D.L. |
| 2017 | Long-term survival following the development of heart failure in an elderly hypertensive population | Sahle, B.; Owen, A.; Wing, L.; Beilin, L.; Krum, H.; Reid, C.; Wing Chair, L.; Reid, C.; Beilin, L.; Brown, M.; Jennings, G.; Johnston, C.; McNeil, J.; Marley, J.; Morgan, T.; Ryan, P.; Shaw deceased, J.; West, M.; MacDonald, G. |
| 2013 | Most individuals with treated blood pressures above target receive only one or two antihypertensive drug classes | Campbell, D.; McGrady, M.; Prior, D.; Coller, J.; Boffa, U.; Shiel, L.; Liew, D.; Wolfe, R.; Stewart, S.; Reid, C.; Krum, H. |
| 2013 | N-terminal B-type natriuretic peptide and the association with left ventricular diastolic function in a population at high risk of incident heart failure: Results of the SCReening Evaluation of the Evolution of New-Heart Failure Study (SCREEN-HF) | McGrady, M.; Reid, C.M.; Shiel, L.; Wolfe, R.; Boffa, U.; Liew, D.; Campbell, D.J.; Prior, D.; Krum, H. |
| 2013 | NT-proB natriuretic peptide, risk factors and asymptomatic left ventricular dysfunction: Results of the SCReening Evaluation of the Evolution of New Heart Failure Study (SCREEN-HF) | McGrady, M.; Reid, C.; Shiel, L.; Wolfe, R.; Boffa, U.; Liew, D.; Campbell, D.; Prior, D.; Stewart, S.; Krum, H. |
| 2013 | Patient preferences and willingness-to-pay for a home or clinic based program of chronic heart failure management: findings from the which? trial | Whitty, J.; Stewart, S.; Carrington, M.; Calderone, A.; Marwick, T.; Horowitz, J.; Krum, H.; Davidson, P.; Macdonald, P.; Reid, C.; Scuffham, P.; Fielding, R. |
| 2019 | Prediction of incident heart failure by serum amino-terminal pro-B-type natriuretic peptide level in a community-based cohort | Campbell, D.J.; Gong, F.F.; Jelinek, M.V.; Castro, J.M.; Coller, J.M.; McGrady, M.; Boffa, U.; Shiel, L.; Wang, B.H.; Liew, D.; Wolfe, R.; Stewart, S.; Owen, A.J.; Krum, H.; Reid, C.M.; Prior, D.L. |
| 2014 | Prolonged impact of home versus clinic-based management of chronic heart failure: extended follow-up of a pragmatic, multicentre randomized trial cohort | Stewart, S.; Carrington, M.; Horowitz, J.; Marwick, T.; Newton, P.; Davidson, P.; Macdonald, P.; Thompson, D.; Chan, Y.; Krum, H.; Reid, C.; Scuffham, P. |
| 2012 | Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension | Mahfoud, F.; Cremers, B.; Janker, J.; Link, B.; Vonend, O.; Ukena, C.; Linz, D.; Schmieder, R.; Rump, L.; Kindermann, I.; Sobotka, P.; Krum, H.; Scheller, B.; Schlaich, M.; Laufs, U.; Böhm, M. |
| 2018 | Risk factor management in a contemporary Australian population at increased cardiovascular disease risk | Campbell, D.J.; Coller, J.M.; Gong, F.F.; McGrady, M.; Prior, D.L.; Boffa, U.; Shiel, L.; Liew, D.; Wolfe, R.; Owen, A.J.; Krum, H.; Reid, C.M. |
| 2022 | Risk factors for asymptomatic echocardiographic abnormalities that predict symptomatic heart failure | Coller, J.M.; Gong, F.F.; McGrady, M.; Shiel, L.; Liew, D.; Stewart, S.; Owen, A.J.; Krum, H.; Reid, C.M.; Prior, D.L.; Campbell, D.J. |
| 2018 | Risk factors for incident heart failure with preserved or reduced ejection fraction, and valvular heart failure, in a community-based cohort | Gong, F.F.; Jelinek, M.V.; Castro, J.M.; Coller, J.M.; McGrady, M.; Boffa, U.; Shiel, L.; Liew, D.; Wolfe, R.; Stewart, S.; Owen, A.J.; Krum, H.; Reid, C.M.; Prior, D.L.; Campbell, D.J. |
| 2007 | Rural and urban differentials in primary care management of chronic heart failure: new data from the CASE study | Robyn, S.; Eckert, K.; Stewart, S.; Phillips, S.; Yallop, J.; Tonkin, A.; Krum, H. |
| 2013 | Telephone support to rural and remote patients with heart failure: the Chronic Heart Failure Assessment by Telephone (CHAT) study | Krum, H.; Forbes, A.; Yallop, J.; Driscoll, A.; Croucher, J.; Chan, B.; Clark, R.; Davidson, P.; Huynh, L.; Kasper, E.K.; Hunt, D.; Egan, H.; Stewart, S.; Piterman, L.; Tonkin, A. |
| 2011 | The WHICH? trial: rationale and design of a pragmatic randomized, multicentre comparison of home- vs. clinic-based management of chronic heart failure patients | Stewart, S.; Carrington, M.; Marwick, T.; Davidson, P.; Macdonald, P.; Horowitz, J.; Krum, H.; Newton, P.; Reid, C.; Scuffham, P. |
| 2016 | The β-blocker to lower cardiovascular dialysis events (BLOCADE) feasibility study: a randomized controlled trial | Roberts, M.A.; Pilmore, H.L.; Ierino, F.L.; Badve, S.V.; Cass, A.; Garg, A.X.; Isbel, N.M.; Krum, H.; Pascoe, E.M.; Perkovic, V.; Scaria, A.; Tonkin, A.M.; Vergara, L.A.; Hawley, C.M.; Levin, A.; Hare, D.; Martin, A.; Wheeler, D.C.; Fulcher, G.; Brown, H.; et al. |
| 2011 | Therapeutic Effects of Human STRO-3-Selected Mesenchymal Precursor Cells and their Soluble Factors in Experimental Myocardial Ischemia | See, F.; Seki, T.; Psaltis, P.; Sondermeijer, H.; Gronthos, S.; Zannettino, A.; Govaert, K.; Schuster, M.; Kurlansky, P.; Kelly, D.; Krum, H.; Itescu, S. |
| 2019 | Tranexamic acid in coronary artery surgery: one-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial | Myles, P.S.; Smith, J.A.; Kasza, J.; Silbert, B.; Jayarajah, M.; Painter, T.; Cooper, D.J.; Marasco, S.; McNeil, J.; Bussières, J.S.; McGuinness, S.; Byrne, K.; Chan, M.T.V.; Landoni, G.; Wallace, S.; Forbes, A.; Esmore, D.; Krum, H.; Tonkin, A.; Buxton, B.; et al. |